Microbial control: Microbial monitoring for biological drug substance manufacturing: an industry perspective
The purpose of this paper is to provide guidance and drive consistency in regards to microbial control for manufacturers of low-bioburden bulk biologics. This paper provides recommendations based on biologics produced using cell cultures such as monoclonal antibody(mAb)-based products and recombinant protein manufacturing process. These recommendations, from the members of the BioPhorum Bioburden Working Group, are intended to assist biopharmaceutical manufacturers develop microbial monitor-ing strategies and product safety assessments. Each manufacturer is unique, therefore, alternative strategies maybe justified and/or qualified.
This paper focuses on the following topics:
● Microbial in-process monitoring during inoculum expansion
● Culture expansion, and protein purification process of bulk drug substances
● Setting alert/action levels limits
● Objectionable organisms in bulk biologics, responding to bioburden excursions
● Assessing impact to product quality
Attached Files
File | |
---|---|
Microbial Monitoring for Biological Drug Substance Manufacturing.pdf |
- Version
- Download 233
- File Size 625.73 KB
- File Count 1
- Create Date 2nd May 2015
- DOI
- Last Updated